Apolipoprotein A-i Integration
Apolipoprotein A-i Integration - Related Videos
07:37
Click-Chemistry Based Fluorometric Assay for Apolipoprotein N-acyltransferase from Enzyme Characterization to High-Throughput Screening
0 Views •
Cited by 2 •
2020
Presented here is a sensitive fluorescence assay to monitor apolipoprotein N-acyltransferase activity using diacylglyceryl peptide and alkyne-phospholipids as substrates with click-chemistry.
07:36
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
0 Views •
Cited by 8 •
2018
We describe a protocol to induce atherosclerosis in the aortic root of ApoE-/- mice fed with an atherogenic diet, through a continuous release of aldosterone. Methods to characterize plaque composition are also described.
10:59
Production of Apolipoprotein C-III Knockout Rabbits using Zinc Finger Nucleases
0 Views •
Cited by 32 •
2013
Recent development in gene targeting tools makes production of knockout (KO) rabbits possible. In the present work, we generated five Apolipoprotein (Apo) C-III KO rabbits using Zinc Finger Nucleases (ZFN). This work demonstrated that ZFN is a highly efficient method to produce KO rabbits.
10:15
Integration of 5G Experimentation Infrastructures into a Multi-Site NFV Ecosystem
0 Views •
Cited by 4 •
2021
The objective of the described protocol is to support the flexible incorporation of 5G experimentation infrastructures into a multi-site NFV ecosystem, through a VPN-based overlay network architecture. Moreover, the protocol defines how to validate the effectiveness of the integration, including a multi-site vertical service deployment with NFV-capable small aerial vehicles.
07:08
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
0 Views •
Cited by 3 •
2016
We describe a high-throughput, multiplex, and targeted proteomic cerebrospinal fluid (CSF) assay developed with potential for clinical translation. The test can quantitate potential markers and risk factors for neurodegeneration, such as the apolipoprotein E variants (E2, E3 and E4), and measure their allelic expression.
FAQs
ApoA-I functions as a cholesterol and phospholipid acceptor at cell membranes through ATP-binding cassette transporter A1. This interaction links membrane lipid efflux to the formation and maturation of HDL-associated transport processes. In neuroscience studies, examining this step helps connect cellular cholesterol balance with broader vascular and neural lipid regulation.
After ApoA-I-associated HDL accepts free cholesterol and phospholipids, lecithin–cholesterol acyltransferase converts free cholesterol into cholesteryl esters within HDL particles. This biochemical change supports continued cholesterol handling by the lipoprotein system. Tracking the sequence helps researchers distinguish initial membrane cholesterol acceptance from subsequent processing within HDL.
ApoA-I integration provides a framework for examining how circulating lipoprotein metabolism relates to blood-brain barrier biology. The connection is important because lipid transport in the circulation may influence how vascular and neural compartments are studied together. This perspective supports investigations of barrier-associated lipid handling without treating brain function as separate from vascular metabolism.
Altered lipid handling can be examined in relation to neuroinflammation and neuronal membrane homeostasis. Because neuronal membranes depend on controlled lipid composition, changes in transport or processing may provide context for studying neural dysfunction. Integrating ApoA-I-related pathways therefore helps researchers connect metabolic observations with cellular membrane regulation and inflammatory processes in the nervous system.
Researchers can organize studies around three linked levels: lipid transport, vascular or blood-brain barrier biology, and neural function. They may then examine how ApoA-I-associated cholesterol and phospholipid handling relates to neuroinflammation or neuronal membrane homeostasis. This structure keeps circulating lipoprotein metabolism connected to specific neuroscience questions rather than analyzing each process in isolation.
ApoA-I integration can support studies seeking biomarkers and therapeutic strategies for neurological disease. Its value comes from connecting altered lipid handling with vascular biology, blood-brain barrier processes, neuroinflammation, and neuronal membrane regulation. These relationships provide a basis for evaluating whether lipid transport patterns are relevant to disease mechanisms or useful for monitoring neurological health.